GSK plc (GSK) 의 후행 P/E는 15.0, 선행 P/E 12.3. 후행 이익수익률은 6.67%, 선행 이익수익률 8.12%. PEG 0.13 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $11.30.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 64/100 4/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 66.5 | -0.75 | 53.95 | 2.17 | 8.00% |
| 2017 | 34.9 | 0.56 | -785.65 | 1.77 | 7.31% |
| 2018 | 16.3 | 0.12 | 13.50 | 1.91 | 6.67% |
| 2019 | 15.1 | 0.56 | 4.64 | 2.08 | 5.64% |
| 2020 | 9.3 | 0.40 | 2.69 | 2.20 | 7.42% |
| 2021 | 11.9 | -2.45 | 2.56 | 2.11 | 7.67% |
| 2022 | 3.9 | -0.36 | 5.52 | 1.99 | 7.30% |
| 2023 | 12.1 | 0.00 | 3.51 | 1.97 | 4.67% |
| 2024 | 21.4 | -0.44 | 4.03 | 1.76 | 4.44% |
| 2025 | 13.2 | 0.11 | 4.51 | 2.31 | 3.40% |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $0.46 | $27.89B | $912M | 3.3% |
| 2017 | $0.78 | $30.19B | $1.53B | 5.1% |
| 2018 | $1.82 | $30.82B | $3.62B | 11.8% |
| 2019 | $2.32 | $33.75B | $4.65B | 13.8% |
| 2020 | $2.86 | $34.1B | $5.75B | 16.9% |
| 2021 | $2.70 | $34.11B | $4.39B | 12.9% |
| 2022 | $2.40 | $29.32B | $4.92B | 16.8% |
| 2023 | $2.40 | $30.33B | $4.93B | 16.2% |
| 2024 | $1.24 | $31.38B | $2.58B | 8.2% |
| 2025 | $2.72 | $31.95B | $5.59B | 17.5% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $4.81 | $4.72 – $5.03 | $45.62B | $45.54B – $45.69B | 7 |
| 2027 | $5.31 | $5.09 – $5.78 | $47.86B | $45.45B – $48.98B | 7 |
| 2028 | $5.56 | $4.99 – $6.82 | $49.08B | $47.87B – $50.39B | 7 |
| 2029 | $5.97 | $5.77 – $6.17 | $50.68B | $49.42B – $52.02B | 2 |
| 2030 | $5.90 | $5.71 – $6.11 | $50.1B | $48.86B – $51.43B | 5 |
